Clinical Trial Update: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SurVaxM vaccine therapy in combination with temozolomide for newly diagnosed glioblastoma (including gliosarcoma); results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• SurVaxM (SurVaxM)
• Temodar (Temozolomide)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Glioblastoma, Gliosarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-02-01